{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T07:56:45Z","timestamp":1788681405002,"version":"build-2803163510"},"reference-count":29,"publisher":"American Medical Association (AMA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"DOI":"10.1001\/jamanetworkopen.2020.2739","type":"journal-article","created":{"date-parts":[[2020,4,14]],"date-time":"2020-04-14T15:33:23Z","timestamp":1586878403000},"page":"e202739","source":"Crossref","is-referenced-by-count":17,"title":["Medicare Part D and Cost-Sharing for Antiretroviral Therapy and Preexposure Prophylaxis"],"prefix":"10.1001","volume":"3","author":[{"given":"Chien-Wen","family":"Tseng","sequence":"first","affiliation":[{"name":"Department of Family Medicine and Community Health, John A. Burns School of Medicine, University of Hawaii, Honolulu"},{"name":"Pacific Health Research and Education Institute, Honolulu, Hawaii"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Adams","family":"Dudley","sequence":"additional","affiliation":[{"name":"School of Medicine, Institute for Health Informatics, University of Minnesota, Minneapolis"},{"name":"School of Public Health, University of Minnesota, Minneapolis"},{"name":"Center for Care Delivery and Outcomes Research, Minneapolis Veterans Affairs Medical Center, Minneapolis, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randi","family":"Chen","sequence":"additional","affiliation":[{"name":"Pacific Health Research and Education Institute, Honolulu, Hawaii"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rochelle P.","family":"Walensky","sequence":"additional","affiliation":[{"name":"Medical Practice Evaluation Center, Division of Infectious Diseases, Massachusetts General Hospital, Boston"},{"name":"Harvard University Center for AIDS Research, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2020,4,14]]},"reference":[{"issue":"48","key":"zoi200134r2","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.15585\/mmwr.mm6848e1","article-title":"Vital signs: status of human immunodeficiency virus testing, viral suppression, and HIV preexposure prophylaxis\u2014United States, 2013-2018.","volume":"68","author":"Harris","year":"2019","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"zoi200134r7","doi-asserted-by":"crossref","DOI":"10.1001\/jamainternmed.2019.7108","article-title":"HIV antiretroviral therapy costs in the United States, 2012-2018.","author":"McCann","year":"2020","journal-title":"JAMA Intern Med"},{"issue":"49","key":"zoi200134r8","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.15585\/mmwr.mm6849a1","article-title":"Nonadherence to any prescribed medication due to cost among adults with HIV infection\u2014United States, 2016-2017.","volume":"68","author":"Beer","year":"2019","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"1","key":"zoi200134r9","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1097\/MLR.0000000000000843","article-title":"Associations between Medicare Part D and out-of-pocket spending, HIV viral load, adherence, and ADAP use in dual eligibles with HIV.","volume":"56","author":"Belenky","year":"2018","journal-title":"Med Care"},{"issue":"11","key":"zoi200134r10","doi-asserted-by":"publisher","first-page":"3566","DOI":"10.1007\/s10461-018-2045-1","article-title":"Why I quit pre-exposure prophylaxis (PrEP)? a mixed-method study exploring reasons for PrEP discontinuation and potential re-initiation among gay and bisexual men.","volume":"22","author":"Whitfield","year":"2018","journal-title":"AIDS Behav"},{"issue":"6","key":"zoi200134r11","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1089\/apc.2018.0290","article-title":"Next-wave HIV pre-exposure prophylaxis implementation for gay and bisexual men.","volume":"33","author":"Golub","year":"2019","journal-title":"AIDS Patient Care STDS"},{"issue":"3","key":"zoi200134r12","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1001\/jama.2019.7521","article-title":"Price increases of protected-class drugs in Medicare Part D, relative to inflation, 2012-2017.","volume":"322","author":"Hwang","year":"2019","journal-title":"JAMA"},{"issue":"9","key":"zoi200134r17","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1001\/jama.2018.7316","article-title":"Out-of-pocket costs for infliximab and its biosimilar for rheumatoid arthritis under Medicare Part D.","volume":"320","author":"Yazdany","year":"2018","journal-title":"JAMA"},{"issue":"20","key":"zoi200134r18","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1001\/jama.2019.4492","article-title":"Specialty drug pricing and out-of-pocket spending on orally administered anticancer drugs in Medicare Part D, 2010 to 2019.","volume":"321","author":"Dusetzina","year":"2019","journal-title":"JAMA"},{"issue":"15","key":"zoi200134r21","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1056\/NEJMp1909798","article-title":"Medicare drug-price negotiation\u2014why now\u2026and how.","volume":"381","author":"Frank","year":"2019","journal-title":"N Engl J Med"},{"issue":"41","key":"zoi200134r24","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.15585\/mmwr.mm6741a3","article-title":"HIV preexposure prophylaxis, by race and ethnicity\u2014United States, 2014-2016.","volume":"67","author":"Huang","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"15","key":"zoi200134r26","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1056\/NEJMp1908688","article-title":"Proposals to redesign Medicare Part D\u2014easing the burden of rising drug prices.","volume":"381","author":"Dusetzina","year":"2019","journal-title":"N Engl J Med"},{"issue":"18","key":"zoi200134r28","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1056\/NEJMp1902692","article-title":"A new safe harbor\u2014turning drug rebates into discounts in Medicare Part D.","volume":"380","author":"Gellad","year":"2019","journal-title":"N Engl J Med"},{"key":"zoi200134r1","unstructured":"HIV.gov. US statistics. Accessed February 6, 2020. https:\/\/www.hiv.gov\/hiv-basics\/overview\/data-and-trends\/statistics"},{"key":"zoi200134r3","unstructured":"Centers for Disease Control and Prevention. HIV surveillance report. Accessed February 6, 2020. https:\/\/www.cdc.gov\/hiv\/statistics\/overview\/index.html"},{"key":"zoi200134r4","unstructured":"HIV.gov. What is \u201cEnding the HIV Epidemic: A Plan for America\u201d? Accessed February 6, 2020. https:\/\/www.hiv.gov\/federal-response\/ending-the-hiv-epidemic\/overview?"},{"key":"zoi200134r5","unstructured":"Centers for Disease Control and Prevention. PrEP. Accessed February 6, 2020. https:\/\/www.cdc.gov\/hiv\/basics\/prep.html"},{"key":"zoi200134r6","unstructured":"US Department of Health and Human Services. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV: cost considerations and antiretroviral therapy. Updated December 18, 2019. Accessed February 6, 2020. https:\/\/aidsinfo.nih.gov\/guidelines\/html\/1\/adult-and-adolescent-arv\/459\/cost-considerations-and-antiretroviral-therapy"},{"key":"zoi200134r13","unstructured":"Kates? J, Dawson? L, Cubanski? J. Quick look: antiretroviral price increases in Medicare Part D. Kaiser Family Foundation. Published December 17, 2019. Accessed February 6, 2020. https:\/\/www.kff.org\/hivaids\/issue-brief\/quick-look-antiretroviral-price-increases-in-medicare-part-d\/#"},{"key":"zoi200134r14","unstructured":"Centers for Medicare & Medicaid Services. Medicare Part D drug spending dashboard & data. Accessed February 6, 2020. https:\/\/www.cms.gov\/Research-Statistics-Data-and-Systems\/Statistics-Trends-and-Reports\/Information-on-Prescription-Drugs\/MedicarePartD"},{"key":"zoi200134r15","unstructured":"Kaiser Family Foundation. Medicare and HIV. Published October 14, 2016. Accessed February 6, 2020. https:\/\/www.kff.org\/hivaids\/fact-sheet\/medicare-and-hiv\/"},{"key":"zoi200134r16","unstructured":"Kaiser Family Foundation. An overview of the Medicare Part D prescription drug benefit. Published November 13, 2019. Accessed February 6, 2020. https:\/\/www.kff.org\/medicare\/fact-sheet\/an-overview-of-the-medicare-part-d-prescription-drug-benefit\/"},{"key":"zoi200134r19","unstructured":"Centers for Medicare & Medicaid Services. Prescription drug plan formulary, pharmacy network, and pricing information files. Accessed February 6, 2020. https:\/\/www.cms.gov\/Research-Statistics-Data-and-Systems\/Files-for-Order\/NonIdentifiableDataFiles\/PrescriptionDrugPlanFormularyPharmacyNetworkandPricingInformationFiles"},{"key":"zoi200134r20","unstructured":"US Department of Health and Human Services. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV: what to start: initial combination regimens for the antiretroviral-naive patient. Updated December 18, 2019. Accessed February 6, 2020. https:\/\/aidsinfo.nih.gov\/guidelines\/html\/1\/adult-and-adolescent-arv\/11\/what-to-start"},{"key":"zoi200134r22","unstructured":"Center for Benefits Access. Full low-income subsidy (LIS)\/extra help (2020)\u201448 states + DC. Accessed February 6, 2020. https:\/\/www.ncoa.org\/wp-content\/uploads\/part-d-lis-eligibility-and-benefits-chart.pdf"},{"key":"zoi200134r23","unstructured":"Centers for Disease Control and Prevention. HIV among people aged 50 and older. Accessed February 6, 2020. https:\/\/www.cdc.gov\/hiv\/group\/age\/olderamericans\/index.html"},{"key":"zoi200134r25","unstructured":"Kaiser Family Foundation. AIDS drug assistance programs (ADAPs). Published August 16, 2017. Accessed February 6, 2020. https:\/\/www.kff.org\/hivaids\/fact-sheet\/aids-drug-assistance-programs\/"},{"key":"zoi200134r27","unstructured":"Cubanski? J, Neuman? T. How will the Medicare Part D benefit change under current law and leading proposals? Kaiser Family Foundation. Published October 11, 2019. Accessed February 6, 2020. https:\/\/www.kff.org\/medicare\/issue-brief\/how-will-the-medicare-part-d-benefit-change-under-current-law-and-leading-proposals\/"},{"key":"zoi200134r29","unstructured":"US Department of Health and Human Services. United States files patent infringement lawsuit against Gilead related to Truvada and Desovy for pre-exposure prophylaxis of HIV. Published November 6, 2019. Accessed February 6, 2020. https:\/\/www.hhs.gov\/about\/news\/2019\/11\/06\/us-files-patent-infringement-lawsuit-against-gilead-pre-exposure-prophylaxis-hiv.html"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2764374\/tseng_2020_oi_200134.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,14]],"date-time":"2020-04-14T15:34:00Z","timestamp":1586878440000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2764374"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,14]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.2739","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,14]]}}}